company background image
688302 logo

Hinova Pharmaceuticals SHSE:688302 Stock Report

Last Price

CN¥32.88

Market Cap

CN¥3.3b

7D

-15.7%

1Y

-39.7%

Updated

27 Mar, 2024

Data

Company Financials +

Hinova Pharmaceuticals Inc.

SHSE:688302 Stock Report

Market Cap: CN¥3.3b

688302 Stock Overview

Hinova Pharmaceuticals Inc., a clinical-stage pharmaceutical company, engages in the development and production of therapeutics for cancers and metabolic syndromes.

688302 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Hinova Pharmaceuticals Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Hinova Pharmaceuticals
Historical stock prices
Current Share PriceCN¥32.88
52 Week HighCN¥78.77
52 Week LowCN¥26.91
Beta0
1 Month Change-12.97%
3 Month Change-35.15%
1 Year Change-39.67%
3 Year Changen/a
5 Year Changen/a
Change since IPO9.24%

Recent News & Updates

Hinova Pharmaceuticals (SHSE:688302) Has Debt But No Earnings; Should You Worry?

Mar 14
Hinova Pharmaceuticals (SHSE:688302) Has Debt But No Earnings; Should You Worry?

Recent updates

Hinova Pharmaceuticals (SHSE:688302) Has Debt But No Earnings; Should You Worry?

Mar 14
Hinova Pharmaceuticals (SHSE:688302) Has Debt But No Earnings; Should You Worry?

Shareholder Returns

688302CN PharmaceuticalsCN Market
7D-15.7%-4.3%-4.9%
1Y-39.7%-11.8%-16.6%

Return vs Industry: 688302 underperformed the CN Pharmaceuticals industry which returned -11.4% over the past year.

Return vs Market: 688302 underperformed the CN Market which returned -14.8% over the past year.

Price Volatility

Is 688302's price volatile compared to industry and market?
688302 volatility
688302 Average Weekly Movement8.7%
Pharmaceuticals Industry Average Movement7.0%
Market Average Movement8.2%
10% most volatile stocks in CN Market11.5%
10% least volatile stocks in CN Market5.1%

Stable Share Price: 688302's share price has been volatile over the past 3 months.

Volatility Over Time: 688302's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2013180n/ahttps://www.hinovapharma.com

Hinova Pharmaceuticals Inc., a clinical-stage pharmaceutical company, engages in the development and production of therapeutics for cancers and metabolic syndromes. It develops drugs based on proteolysis targeting chimera and deuteration technology. The company’s products pipeline includes HC-1119, a product in phase III clinical trials with castration resistant prostate cancer indications; HP501, a product in phase II clinical trials for the treatment of hyperuricemia and gout; HP558, a product in phase II clinical trials to treat various late-stage cancers; and HP518, an oral PROTAC drug in phase I clinical trials with a focus on to solve the drug resistance of AR-mutated prostate cancer.

Hinova Pharmaceuticals Inc. Fundamentals Summary

How do Hinova Pharmaceuticals's earnings and revenue compare to its market cap?
688302 fundamental statistics
Market capCN¥3.26b
Earnings (TTM)-CN¥294.47m
Revenue (TTM)n/a

0.0x

P/S Ratio

-11.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
688302 income statement (TTM)
RevenueCN¥0
Cost of RevenueCN¥0
Gross ProfitCN¥0
Other ExpensesCN¥294.47m
Earnings-CN¥294.47m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

Apr 18, 2024

Earnings per share (EPS)-2.97
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio3.1%

How did 688302 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.